Becton, Dickinson and Company (NYSE:BDX) Releases Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Becton, Dickinson and Company (NYSE:BDX) posted its earnings results on Thursday. The medical instruments supplier reported $3.17 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20, RTT News reports. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter in the prior year, the business earned $2.86 earnings per share. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. Becton, Dickinson and Company updated its FY24 guidance to $12.95-13.15 EPS.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX traded up $4.31 during mid-day trading on Thursday, reaching $238.03. 1,255,843 shares of the company traded hands, compared to its average volume of 1,379,163. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32. The firm has a market cap of $68.77 billion, a PE ratio of 55.41, a PEG ratio of 1.94 and a beta of 0.45. The company’s 50 day moving average price is $238.75 and its 200-day moving average price is $240.71. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 90.05%.

Insider Transactions at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BDX. Barclays raised their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. Raymond James upped their price target on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus target price of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.